Compare Shell PLC (SHEL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs Twist Bioscience Corp — how do they compare? Shell PLC trades at $87.12 (market cap $235.24B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Shell PLC is far larger — about 43.2× Twist Bioscience Corp's market cap, and Shell PLC pays a 3.63% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SHEL | TWST | |
|---|---|---|
Market Cap | $235.24B | $5.45B |
Sector | Energy | Health |
52-Week High | $94.15 | $102.88 |
52-Week Low | $70.31 | $24.16 |
Enterprise Value | $287.77B | $5.37B |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
